Pfizer CEO Ian Read's long-anticipated split-up decision is looming. What if his answer is no?

Pfizer HQ

Investors have been salivating for years over the prospect of Pfizer splitting into two separate companies. And now, D-day--decision day--is approaching. CEO Ian Read has promised to decide on a breakup by year's end.

As Bernstein analyst Tim Anderson points out in a Tuesday note, most market watchers see the big break as a foregone conclusion. After all, Pfizer has reorganized internally and made deals to augment its established products unit, including its big Hospira buy last year. Even Pfizer’s tried-and-failed megamerger attempts seemed designed to beef up both sides of the company in preparation for a subsequent split.

But what if Pfizer’s answer is no?

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Read has repeatedly said that he might decide against the big divorce. Those caveats might have been viewed as perfunctory, but counting on that fact would be unwise, Anderson figures.

“In our opinion, splitting up made clear sense when the long-term Pfizer model seemed to lack growth,” Anderson said, likening Pfizer’s split-up approach to the financial industry’s “good bank” and “bad bank” splits after the 2008 financial crisis. The “innovative” products unit was clearly the “good” bit, with a clearer path to growth, while the “established” products side, based as it was on off-patent products, was the slower-growing “bad” bit.

“Fast forward to today, however and Pfizer appears to have long-term growth in front of it across both units, in part because of the success of products like Ibrance and Prevnar-13v, and the added revenue stream from the 2015 Hospira acquisition,” Anderson writes.

Pfizer’s recent sales figures show just how much Ibrance and Prevnar are delivering to the company’s top line. The breast cancer drug Ibrance has beat all launch expectations, and Prevnar sales have been leaping quarter after quarter, helping fuel recent revenue beats. For the first quarter, Ibrance brought in $429 million, $30 million ahead of analyst estimates, while Prevnar racked up $1.5 billion, compared with street forecasts of $1.4 billion.

Meanwhile, given the state of the stock market--where specialty pharma is suffering--Pfizer might not see much payoff for investors in hiving off its established products business.

Citing a meeting with Read last week, Anderson said Pfizer management sees current P/E multiples as complicating the decision to split. Plugging a low-end multiple of 8X or 9X earnings into the established products equation “suggests splitting up creates no upside,” and though Pfizer has been arguing that its business rates a higher multiple, there’s no guarantee the market would deliver. And the higher Pfizer’s own stock price goes, the less likely it might be that the company breaks up, Anderson figures.

Even so, Bernstein sees Pfizer coming down on the side of a split by year’s end: “[I]f it doesn’t, investors will likely be disappointed,” Anderson writes.

Then again, Read might just delay the decision once more if the right megamerger opportunity came along. Last week, the CEO said he’s no longer interested in chasing the sort a tax inversion deal a la its now-canceled $160 billion Allergan buy. But he wouldn’t rule out another outsized acquisition, so long as it makes financial sense for shareholders. 

“If you believe you can reorganize your research into productive smaller units, there is a logic to consolidation of the industry by taking out duplicative expenses,” especially if the two companies can squeeze out some serious savings, Read said at Bernstein’s Strategic Decisions Conference last week.

Related Articles:
Pfizer's done with tax inversions, but megamergers? Bring 'em on, CEO says
Pfizer slots Anacor into deal roster with $4.5B buyout
Medivation opens books to Pfizer, Amgen as bidders circle: Reuters
Prevnar, Ibrance beat again to help Pfizer pass Q1 forecasts
Don't worry, Pfizer and Allergan. Treasury just did you a favor
What would Pfizer do without Allergan--and Allergan without Pfizer?
With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&A

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.